What approvals has Alecensa (alectinib) received, and for which cancers?
Alecensa (alectinib) has been approved in multiple countries for ALK-positive non-small cell lung cancer (NSCLC), with indications that expanded as more trial evidence became available. The exact wording of each approval depends on regulator and line of therapy (for example, first-line versus after prior treatment). [1][2]
How did the approval timeline progress in the US (FDA) versus other regulators?
In the United States, Alecensa’s approval history followed a stepwise pattern typical for oncology drugs: an initial approval based on early evidence in a defined patient group, followed by expanded approvals as additional studies supported broader use (including earlier lines of therapy). [1]
Other regulators (such as EMA in Europe) generally followed parallel expansion as new clinical data were reviewed and incorporated into label updates. [2]
What were the key label expansions (first-line vs after chemotherapy/targeted therapy)?
Alecensa’s label has expanded from use in patients with ALK-positive metastatic NSCLC after prior treatment to broader settings that include first-line treatment for ALK-positive metastatic NSCLC, depending on the regulator and the supported trial population. [1][2]
Did Alecensa receive approvals based on specific clinical trial programs?
Yes. Alecensa’s approvals and label expansions were tied to clinical trial results in ALK-positive NSCLC, including studies designed to support efficacy in different treatment settings (for example, comparing outcomes versus other standard approaches in later-line settings and evaluating benefit in earlier-line therapy). [1][2]
Has Alecensa’s approval ever been limited or changed by regulator actions?
Drug labels for targeted oncology therapies can change over time as regulators update indications, restrict eligibility criteria, or incorporate new safety/benefit information. Alecensa’s label updates reflect these ongoing regulatory reviews as new evidence accumulates. [1][2]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208459
- https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa